Delivery Order SPE2DB22D3301-SPE2DB24FY5PR
- Not listed
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,111.11, is for the delivery of VENOFER 100 MG/5 ML VIAL 5ML, a medical product. The contract has an ultimate completion date of January 10, 2024 and is structured as a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,181.74 firm fixed-price delivery order is for the provision of VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product. The contract has an ultimate completion date of October 21, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $7,370.46 firm-fixed-price delivery order is for the pharmaceutical product Venofer 100 mg/5 ml vial 5 ml. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical. The award is for VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product, with a ceiling value of $2,907.09. The contract has a period of performance through December 4, 2024 and uses a Firm Fixed Price pricing structure. This contract is not designated as a set-aside and...
- This federal contract award is for the delivery of Venofer 100 mg/5 ml vials, a pharmaceutical product, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract award has a ceiling value of $3,553.46 and an ultimate completion date of December 22, 2023. It is a delivery order contract with a firm fixed price pricing type. The contract is not designated with a set-aside....
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of pharmaceutical product Venofer, a 100 mg/5 ml injectable iron supplement, with a ceiling value of $2,070.58 and a completion date of May 6, 2024. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and does not have a set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government,...
- This federal contract award is for the delivery of VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $1,902.52 and is a firm fixed-price delivery order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product. The award is a delivery order with a firm fixed price of $1,022.90 and an ultimate completion date of January 29, 2025. This contract award is not designated with a set-aside requirement. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role...
- This federal contract award was made by the Defense Logistics Agency (DLA), a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,107.34 firm fixed-price delivery order is for the supply of VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product. The award is not a set-aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, designated as SPE2DX, which provides global pharmaceutical support to...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical company. The contract is for the delivery of VENOFER 100 MG/5 ML VIAL 5ML, a pharmaceutical product, with a firm fixed price of $3,150.06 and a completion date of February 5, 2024. This contract was not set aside for any particular business type. Amerisourcebergen Drug Corp is the prime contractor and has an...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB24FY5PRDelivery Order
The summary is as follows: This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $7,203.58, is for the delivery of Venofer 100 mg/5 ml vial (5 ml) to support military and government healthcare programs. The contract has an ultimate completion date of April 29, 2024 and is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense and other federal agencies. The contract award has no set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 4/26/24 |